Treatment of ECD-Sema5A-transfected melanoma cells with Trametinib, a specific MEK inhibitor used for melanoma therapy [35, 36], significantly reduced the ability of Sema5A- overexpressing cells to migrate (Fig. 2g, Additional file 2: Figure S2), thus indicating that Sema5A-dependent cellular migration is mediated by activation of MEK pathway. Here, SEMA5A is linked to melanoma.